Achieving Accurate Results in Antibody-Based Drug Discovery with the FcResolv™ NOG Portfolio
Researchers who work with antibody-based therapies find that murine Fc gamma receptors (FcγRs) can confound preclinical study results, causing false positives or false negatives that lead to incorrect conclusions and derail drug discovery. By knocking out these receptors, FcResolv™ NOG models provide clarity in antibody-based drug studies, offering greater confidence and more translatable data while utilizing fewer resources.
This webinar introduces the FcResolv™ NOG Portfolio, including the FcResolv™ NOG, FcResolv™ hIL-15 NOG, and FcResolv™ huNOG, and demonstrate the utility of these models for research involving antibody-based therapeutics. Results of a recent study demonstrating how the FcResolv™ huNOG revealed both efficacy and pharmacodynamic indicators of a clinically-relevant immune checkpoint inhibitor when compared to donor-matched huNOG will be presented.
View this webinar to learn:
- How Fc gamma receptors on residual murine immune cells in immunodeficient mice can cause misleading results, including both false positives and false negatives
- Which mouse Fc receptors are absent in FcResolv™ NOG models and the strategy used to functionally delete them
- Which human immune cells are supported by the FcResolv™ NOG and FcResolv™ hIL-15 NOG strains
- Functional implications of murine Fc gamma receptors in humanized immune system mice on the evaluation of efficacy and pharmacodynamic indicators for antibody-based drugs
- Case studies which demonstrate how removing confounding murine Fc gamma receptors improves accuracy of results in FcResolv™ NOG models over standard NOG models
Dr. Janell Richardson
Director, R & D
Janell Richardson has 15 years of in vivo pharmacology experience. She received her doctorate in 2012 from Georgetown University in Pharmacology. She continued on to a post-doctoral fellowship and subsequently moved into industry in 2015. In the commercial sector, she led an early target identification in vivo pharmacology team. In 2018, she joined Taconic as a field scientist and now leads Taconic’s global R&D efforts.